APVO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.4M
-5.8%
6.8M
+14.0%
6.0M
-21.2%
7.6M
+22.2%
6.2M
R&D
3.7M
-5.8%
3.9M
+11.0%
3.5M
-12.6%
4.0M
+21.5%
3.3M
SG&A
2.7M
-5.7%
2.9M
+18.4%
2.5M
-31.0%
3.6M
+23.1%
2.9M
Operating Income
-6443000
+5.8%
-6837000
-14.0%
-5996000
+21.2%
-7610000
-22.2%
-6226000
EBITDA
-6411000
+5.7%
-6802000
-15.0%
-5915000
+21.8%
-7561000
-22.4%
-6177000
Net Income
-6356000
+5.1%
-6697000
-15.3%
-5806000
+23.1%
-7549000
-21.7%
-6204000
EPS (Basic)
$-5.31
+17.2%
$-6.41
$-40.14
+73.5%
$-151.29
EPS (Diluted)
$-5.31
+17.2%
$-6.41
$-40.14
+73.5%
$-151.29
Shares (Diluted)
1.2M
+12.8%
1.1M
224.9K
+448.5%
41.0K
Aptevo Therapeutics (APVO) — Financials